In early clinical trials, these drugs, along with inhibitors that directly block YAP-TEAD interactions, have been found to be well tolerated and show antitumor activity in NF2-mutant cancers and mesothelioma, a condition known to often have NF2 alterations (NCT04665206, NCT05228015, NCT04857372) [23]. Here, YAP1 is linked to cancer.